Baxter International Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – BAX

(NYSE:BAX), LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. […]

CBP Management Enters Third Atlantic Province with New PEI Mandate

OTTAWA, Nov. 03, 2025 (GLOBE NEWSWIRE) — CBP Management, the real estate management services division of Colonnade BridgePort, has officially expanded into a third Atlantic Canada province with the property management and leasing mandate for County Fair Mall on Prince Edward Island. Located in Summerside, the province's second-largest city, the privately-owned 244,372 square foot enclosed

Baxter International Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – BAX

Baxter International Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – BAX GlobeNewswire November 03, 2025 LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations

CBP Management Enters Third Atlantic Province with New PEI Mandate

CBP Management Enters Third Atlantic Province with New PEI Mandate Strengthening its regional portfolio and presence in high-performing secondary markets GlobeNewswire November 03, 2025 OTTAWA, Nov. 03, 2025 (GLOBE NEWSWIRE) — CBP Management, the real estate management services division of Colonnade BridgePort, has officially expanded into a third Atlantic Canada province with the property management

Advanced Injury Care Clinic Reinforces Position as Auto Accident Treatment Specialists

NASHVILLE, TN, Nov. 03, 2025 (GLOBE NEWSWIRE) — NASHVILLE, TN – November 01, 2025 – – Advanced Injury Care Clinic, a Nashville-based chiropractic and medical treatment center, continues to demonstrate excellence in treating auto accident injuries throughout the greater Nashville area, backed by consistently positive patient reviews and a decade of specialized experience serving Tennessee

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

(NASDAQ:SNDX), NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual

Advanced Injury Care Clinic Reinforces Position as Auto Accident Treatment Specialists

Advanced Injury Care Clinic Reinforces Position as Auto Accident Treatment Specialists GlobeNewswire November 03, 2025 NASHVILLE, TN, Nov. 03, 2025 (GLOBE NEWSWIRE) — NASHVILLE, TN – November 01, 2025 – – Advanced Injury Care Clinic, a Nashville-based chiropractic and medical treatment center, continues to demonstrate excellence in treating auto accident injuries throughout the greater Nashville

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 GlobeNewswire November 03, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast,

Syndax Announces Compelling Revuforj(R) (revumenib) and Niktimvo(TM) (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

(NASDAQ:SNDX), – 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – – Axatilimab abstracts highlight potential for long-term benefit in R/R chronic GVHD and

Syndax Announces Compelling Revuforj(R) (revumenib) and Niktimvo(TM) (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

Syndax Announces Compelling Revuforj(R) (revumenib) and Niktimvo(TM) (axatilimab-csfr) Data Accepted for Presentation at ASH 2025 GlobeNewswire November 03, 2025 – 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R,

Scroll to Top